Home / People / David Dennis
Portrait ofDavid Dennis

David Dennis

Partner

Contact
CMS Cameron McKenna Nabarro Olswang LLP
1 West Regent Street
Glasgow
G2 1AP
United Kingdom
Languages English

David Dennis is a partner in the CMS Technology Team. He enjoys a wide range of commercial, technology and intellectual property-related work, with a particular interest in the life sciences sector.

David advises a full spectrum of clients ranging from start-ups to FTSE100 companies. His work spans a similar range, from small, initial agreements such as heads of terms and confidentiality agreements through to strategic licensing and long-term collaboration agreements. David is qualified in both England and Scotland and has worked in Edinburgh, Glasgow and London.

more less

Relevant experience

  • “Big Six” UK utility company in relation to drafting a template agreement for procuring services.
  • A Russell Group University on its supply agreement for a radioactive tracer.
  • An award-winning oncology start-up on its key research and licensing agreements.
  • An international biopharmaceuticals company on its world-wide re-acquisition of product rights.
  • A listed UK pharma company on its co-development agreement regarding drug-resistant bacteria.
  • A “Big Pharma” company on its gene therapy collaboration and option agreement, worth over USD 300m.
more less

Education

  • 2007 – LL.M., Glasgow University, Glasgow
  • 2006 – LL.B., Glasgow University, Glasgow
more less

Feed

18/04/2024
In View: Life Sciences & Healthcare - What's new in AI Regulation and Data...
 We are delighted to invite you to the CMS In View: Life Sciences & Healthcare - What’s New in AI Regulation and Data Protection? event taking place on Thursday 18 April at our London Cannon Place offices. The seminar will focus on key AI and data protection topics relevant to life sciences and healthcare where you will hear from industry and regulatory experts from the ICO, Health Research Authority, UCL, the Wellcome Trust and CMS UK specialists. If you would like to attend this event, please register via the button below.
23/01/2024
Universities and the Procurement Act 2023
The legal landscape in the UK for procurement is changing this year. This quick update summarises the impact this may have on UK universities.To the extent a university considers its activities to be...
15/11/2023
Clear Exclusion of Liability Leads to Reverse Summary Judgment
A recent High Court judgment provides clear guidance on contractual liability, particularly on exclusions of liability and the application of the Unfair Contract Terms Act 1977 (“UCTA”).The dispute...
03/11/2023
Supply chain disasters – history repeats itself
Recent headlines regarding supply chain failures have similarities with a disaster from the 19th Century. This article looks at the failures and suggests ways to reduce future risk.Back­groundThis Halloween...
24/08/2023
Enforcing licence option rights: is it worth it?
The recent decision in Exelogen Inc v. University of Birm­ing­ham high­lights the challenges of enforcing option agreements for intellectual property rights and the difficulties of proving loss of profit-earn­ing...
15/08/2023
Royalties on Revenue: can you Deduct Rebates?
The English High Court recently decided a dispute over royalty payments in relation to a pharmaceutical product. The main issue was whether rebates given to industry intermediaries could be deducted from...
10/08/2023
Lessons to be learnt from the recent data breaches in the public sector
Following on from the recently reported data breaches by Police Services of Northern Ireland (PSNI) and the Electoral Commission (EC), organisations should take a step back and re-evaluate their compliance...
27/07/2023
Summary: UK response to clinical trials consultation
The UK government has published its response to a consultation on legislative proposals for clinical trials, outlining its proposed changes to the regulation of clinical trials in the UK. The response...
10/02/2021
Life Sciences - The road to recovery
Covid-19 has put the life sciences industry in the spotlight. The sector has pulled together to care for those impacted by the virus and in the race to find a vaccine. There have been col­lab­or­a­tions...
11/05/2020
AI in Life Sciences
Artificial intelligence is not new: the term itself was coined over 60 years ago. However, the convergence of data volume, processing power and technical capability has convinced many that the AI era...
06/02/2020
World First as AI-designed Drug Starts Clinical Trials 
The UK-based AI drug discovery company, Exscientia, has been hailed as reaching a huge milestone: the world’s first AI-designed drug to enter Phase 1 clinical trials. Why is this a big deal? And are...
03/12/2019
Labour proposes Life Sciences Revolution
As summarised in our earlier article, here, Jeremy Corbyn has made radical proposals to change the United Kingdom’s life sciences industry and patent regime. The proposals impact the research and development...